FDAnews
www.fdanews.com/articles/183980-ad-comm-gives-thumbs-up-to-gene-therapy-for-inherited-eye-disease

Ad Comm Gives Thumbs Up to Gene Therapy for Inherited Eye Disease

October 16, 2017

An FDA advisory committee unanimously endorsed Spark Therapeutics’ gene therapy for vision loss.

The 16-0 vote by the Cellular, Tissue, and Gene Therapies Advisory Committee came in response to the question of whether Spark’s Luxturna¬† (voretigene neparvovec) has “an overall favorable risk-benefit profile” for treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, an inherited condition that can lead to progressive deterioration of vision and total blindness.

The vote came after the committee heard testimony on the life-changing effects of the medication from several patients who had received it. The committee also reviewed evidence from a Phase 3 clinical trial.

View today's stories